cerca CERCA
Martedì 30 Novembre 2021
Aggiornato: 03:08
Temi caldi


comunicato stampa

Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of the April 2021$8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative.

comunicato stampa

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics (MDx) developer Seegene Inc., (KQ 096530) is addressing the needs of small, mid-sized, and large hospitals and COVID-19 laboratories with its fully automated STARlet-AIOS: All-in-One System (AIOS). First unveiled at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta, the modular system supports a "hands-free" PCR workflow, automating everything from nucleic acid extraction to the inte...

YES EcoCoat™ HVM to Help Customer Fulfill Large NIH Contract for Rapid COVID Antibody Testing Devices

FREMONT, Calif., July 26, 2021 /PRNewswire/ -- YES (Yield Engineering Systems, Inc.), a leading manufacturer of process equipment for semiconductor advanced packaging, life sciences and "More-than-Moore" applications, today announced that one of its customers has been awarded a multimillion-dollar contract by the US's National Institutes of Health to manufacture a new COVID testing device for mass distribution. The award was made possible through the NIH's Rapid Acceleration of Diagnostics (RADxS...

Team Bahrain Victorious Partners with iXensor to Deploy COVID-19 Antigen Testing for the Reopened Cycling Races

PARIS, July 19, 2021 /PRNewswire/ -- iXensor (6734.TWO), the pioneer of mobile health, announces today its sponsorship of the Team Bahrain Victorious. iXensor provides the fully digitalized COVID-19 rapid testing solution consisting of the PixoTest COVID-19 antigen test, digital health pass app and a cloud-based management web portal for the champion cycling team of the Tour de France 2021 to prevent transmissions of SARS-CoV-2.

Precision Toxicology consortium aims to protect human health from effects of harmful chemicals

BRUSSELS, March 9, 2021 /PRNewswire/ -- A major research project to shape regulation and policy on chemical safety without the use of animal testing has been launched with the aid of €19.3M funding from the European Commission under H2020 program. Led by the University of Birmingham and involving 15 European and US organisations, PrecisionTox aims to protect human health from the toxic effects of chemicals found in people's homes, food and the environment. The Precision Toxicology consortium will...

Wondfo - Neutralizing antibody testing, antigen testing and PCR key in battle against COVID-19 in 2021

GUANGZHOU, China, Feb. 1, 2021 /PRNewswire/ -- Wondfo is ramping up neutralizing antibody, antigen and PCR tests to address the evolving demands for COVID-19 testing globally. As countries draw up plans to deal with the new wave of infections amidst the pandemic while vaccination programmes are rolled out, Wondfo remains resolute and agile to provide healthcare authorities with the specific tests they need to apply appropriate testing strategies that can help bring the pandemic under control.

Bioplastics successfully meet all EU safety standards

BERLIN, Oct. 30, 2020 /PRNewswire/ -- Products made from bio-based plastics must undergo the same testing procedures as conventional plastic products to access the market of the European Union (EU). Thereby a health risk for consumers is excluded. Plastics intended to be certified as biodegradable or compostable require additional tests. "Products made of bioplastics thus pass even more tests than conventional plastic products," explains Hasso von Pogrell, Managing Director of European Bioplastic...

Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany

IRVINE, California, Oct. 6, 2020 /PRNewswire/ -- Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping tests, provided by PathoNext lab in Leipzig, Germany. Breast cancer patients in Germany will now have access to state-of-the art genomic profiling in their own country.

ora in
Prima pagina
in Evidenza